Scavenger receptor class BI (SR-BI) mediates uptake of CPX-351 into K562 leukemia cells

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.
   PubMed Web of Science ®Google Scholar
• Ofran Y, Rowe J. How many cycles of 7 + 3 and for whom? Leukemia. 2016;30:1796.
   PubMed Web of Science ®Google Scholar
• Roboz GJ. Novel approaches to the treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2011;2011:43–50.
   PubMedGoogle Scholar
• DiNardo CD, Cortes JE. New treatment for acute myelogenous leukemia. Expert Opin Pharmacother. 2015;16:95–106.
   PubMed Web of Science ®Google Scholar
• Tardi P, Johnstone S, Harasym N, et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res. 2009;33:129–139.
   PubMed Web of Science ®Google Scholar
• Dicko A, Kwak S, Frazier AA, et al. Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin. Int J Pharm. 2010;391:248–259.
   PubMed Web of Science ®Google Scholar
• Feldman EJ, Kolitz JE, Trang JM, et al. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk Res. 2012;36:1283–1289.
   PubMed Web of Science ®Google Scholar
• Lim WS, Tardi PG, Dos Santos N, et al. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leuk Res. 2010;34:1214–1223.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014;123:3239–3246.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Goldberg SL, Feldman EJ, et al. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer. 2015;121:234–242.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Uy GL, Cortes JE, et al. Final results of a phase III randomized trial of CPX-351 versus 7 + 3 in older patients with newly diagnosed high risk (secondary) AML. Am Soc Clin Oncol. 2016;15_suppl:7000.
   Google Scholar
• Nikanjam M, Capparelli EV, Lancet JE, et al. Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment. Cancer Chemother Pharmacol. 2018;81:171–178.
   PubMed Web of Science ®Google Scholar
• Walter RB, Othus M, Orlowski KF, et al. Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm. Haematologica. 2018;103:e106–e109.
   PubMed Web of Science ®Google Scholar
• Kim P, Gerhard G, Harasym TO, et al. Improved selectivity against acute myeloid leukemia (AML) blasts over normal hematopoietic progenitors for cytarabine: daunorubicin delivered as CPX-351 liposome injection. Blood. 2009;114:2071.
   Web of Science ®Google Scholar
• Tardi P, Wan CPL, Mayer L. Passive and semi-active targeting of bone marrow and leukemia cells using anionic low cholesterol liposomes. J Drug Target. 2016;24:797–804.
   PubMed Web of Science ®Google Scholar
• Kessel D, Hall TC, Rosenthal D. Uptake and phosphorylation of cytosine arabinoside by normal and leukemic human blood cells in vitro. Cancer Res. 1969;29:459–463.
   PubMed Web of Science ®Google Scholar
• Tidefelt U, Sundman-Engberg B, Paul C. Intracellular uptake and cytotoxic effect in vitro of doxorubicin and epirubicin in human leukemic and normal hematopoietic cells. Cancer Chemother Pharmacol. 1991;29:7–12.
   PubMed Web of Science ®Google Scholar
• Sercombe L, Veerati T, Moheimani F, et al. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286.
   PubMed Web of Science ®Google Scholar
• Miller CR, Bondurant B, McLean SD, et al. Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry. 1998;37:12875–12883.
   PubMed Web of Science ®Google Scholar
• Lee KD, Hong K, Papahadjopoulos D. Recognition of liposomes by cells: in vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density. Biochim Biophys Acta. 1992;1103:185–197.
   PubMed Web of Science ®Google Scholar
• Amin K, Wasan KM, Albrecht RM, et al. Cell association of liposomes with high fluid anionic phospholipid content is mediated specifically by LDL and its receptor, LDLr. J Pharm Sci. 2002;91:1233–1244.
   PubMed Web of Science ®Google Scholar
• Rigotti A, Acton SL, Krieger M. The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids. J Biol Chem. 1995;270:16221–16224.
   PubMed Web of Science ®Google Scholar
• Ryeom SW, Silverstein RL, Scotto A, et al. Binding of anionic phospholipids to retinal pigment epithelium may be mediated by the scavenger receptor CD36. J Biol Chem. 1996;271:20536–20539.
   PubMed Web of Science ®Google Scholar
• Sakai-Kato K, Sakurai M, Takechi-Haraya Y, et al. Involvement of scavenger receptor class B type 1 and low-density lipoprotein receptor in the internalization of liposomes into HepG2 cells. Bba-Biomembranes. 2017;1859:2253–2258.
   PubMed Web of Science ®Google Scholar
• Düzgüneş N, Nir S. Mechanisms and kinetics of liposome-cell interactions. Adv Drug Deliv Rev. 1999;40:3–18.
   PubMed Web of Science ®Google Scholar
• Rhainds D, Brissette L. The role of scavenger receptor class B type I (SR-BI) in lipid trafficking. defining the rules for lipid traders. Int J Biochem Cell Biol. 2004;36:39–77.
   PubMed Web of Science ®Google Scholar
• Shen WJ, Hu J, Hu Z, et al. Scavenger receptor class B type I (SR-BI): a versatile receptor with multiple functions and actions. Metabolism. 2014;63:875–886.
   PubMed Web of Science ®Google Scholar
• Xu Y, McKenna RW, Wilson KS, et al. Immunophenotypic identification of acute myeloid leukemia with monocytic differentiation. Leukemia. 2006;20:1321–1324.
   PubMed Web of Science ®Google Scholar
• Casasnovas RO, Slimane FK, Garand R, et al. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome. Leukemia. 2003;17:515–527.
   PubMed Web of Science ®Google Scholar
• Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet. 2000;24:236–244.
   PubMed Web of Science ®Google Scholar
• Jenny Hanbi KPT, Shin ES, Mayer L, Wasan KM, editors. Scavenger receptor class B type I (SR-BI) expression levels modulate CPX-351 uptake within cancer cells. Montréal: Canadian Society for Pharmaceutical Sciences; 2014.
   Google Scholar
• Twiddy AL, Cox ME, Wasan KM. Knockdown of scavenger receptor class B type I reduces prostate specific antigen secretion and viability of prostate cancer cells. Prostate. 2012;72:955–965.
   PubMed Web of Science ®Google Scholar
• Rajora MA, Zheng G. Targeting SR-BI for cancer diagnostics, imaging and therapy. Front Pharmacol. 2016;7:326.
   PubMed Web of Science ®Google Scholar